

## 2004 VARIETY RECOMMENDATIONS FOR SPRING AND WINTER CANOLA

**Table 1. Recommended Spring Canola Hybrids and Varieties**

Variety	Days from Planting to Maturity <sup>1</sup>	(2 Year) Yield <sup>2,5</sup> (t/ha)	(3 Year) Yield <sup>3,5</sup> (t/ha)	Free Fatty Acids <sup>3</sup> (%)	Brown Seeds <sup>3</sup> (%)	Lodging <sup>4</sup> 1 = erect 5 = flat	Distributor
45H21 <sup>8</sup>	93 <sup>6</sup>	2.72		0.40 <sup>7</sup>	1.4 <sup>7</sup>	2.0 <sup>6</sup>	Pioneer Hybrid
Hyola 357RR <sup>8</sup>	97	2.51	2.57	0.43	1.8	2.2	Advanta Seeds
InVigor 2643 <sup>9</sup>	98	2.64	2.68	0.62	2.7	2.0	Bayer CropScience
Hyola 401	99	2.63	2.69	0.37	1.6	2.1	Advanta Seeds
OAC Tornado	99	2.59	2.56	0.62	2.8	1.7	Bonis & Company Ltd.
Canterra 1492CA	100	2.55	2.46	0.82	4.2	1.6	Advantage Seed Growers
OAC Hurricane	100	2.44	2.44	0.57	2.4	1.8	Bonis & Company Ltd.
Senator	100	2.42	2.38	0.72	3.7	1.6	Bonis & Company Ltd.

Most of the entries are hybrids except for the OAC varieties and Senator.

<sup>1, 3, 4</sup> Values shown are averages of 9, 14, and 8 public trials, respectively, grown in 2001 - 2003.

<sup>2</sup> Values shown are averages of 10 public trials grown in 2002 and 2003.

<sup>5</sup> 1 t/ha = 893 lb/ac.

<sup>6, 7</sup> The values for this variety are averages of 5 and 10 public trials, respectively, grown in 2002 and 2003.

<sup>8</sup> These varieties are Roundup Ready<sup>TM</sup>.

<sup>9</sup> This variety is Liberty Link<sup>TM</sup>.

**Table 2. Recommended Winter Canola Varieties**

Variety	Yield <sup>1,2</sup> (t/ha)	Winter <sup>3</sup> Survival (%)	Maturity <sup>4</sup> Date (July)	Lodging <sup>5</sup> 1 = erect 5 = flat	Blackleg Rating <sup>6</sup> 0 = none 4 = dead	Distributor
Baldur	3.31	77.9	10	1.6	-	C&M Seeds
Kronos	3.47	83.5	10	1.4	-	C&M Seeds

Baldur and Kronos are hybrids.

<sup>1</sup> 1 t/ha = 893 lb/ac = 17.86 bu/ac

<sup>2,3,4,5</sup> Values shown are averaged for 6, 3, 2, and 4 trials, respectively, harvested in 2001 - 2002.

<sup>6</sup> There was no Ontario Blackleg data, however, both hybrids had medium to low ratings in European trials.